Uromitexan (** - Uromitexan (brand name) - Mesna (generic name) - Mesnex **)
Other Medications
Description
Uromitexan (also known as Mesna) is a medication primarily used to protect the bladder from damage caused by certain chemotherapy drugs, particularly ifosfamide and cyclophosphamide. It is not a direct treatment for colorectal cancer itself but is used as a supportive care medication during chemotherapy. It works by binding to these chemotherapy drugs in the urine, forming a less toxic compound that is then excreted, preventing bladder irritation and potential damage. While the provided trial (NCT07255664) is investigating T-cell therapy for metastatic CRC, Uromitexan is listed as a drug combined with it in some CRC trials, likely for patients receiving chemotherapy alongside the experimental therapy. It's important to note that Uromitexan's role is supportive, not curative, for the cancer.
Mechanism of Action
Uromitexan (Mesna) is a thiol compound. It works by reacting with the toxic metabolites of certain chemotherapy drugs (like ifosfamide and cyclophosphamide) in the urinary tract. This reaction forms non-toxic, water-soluble compounds that are easily excreted by the kidneys, thereby preventing these toxic metabolites from damaging the bladder lining.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.